MTRG-banner

Medical Technology Research Group

Past projects and grants

 Projects

Schizophrenia-mtrg-200-200

Cost and Impact of Non-Treating Severe Mental Illnesses (SMIs): The Case Study of Schizophrenia
European Brain Council

Find out more here.

 


 

HTA-mtrg-200-200

Study on impact analysis of policy options for strengthened EU cooperation on Health Technology Assessment 
European Commission

Find out more here.

 


 

Diabetes-mtrg-200-200

Diabetes Expenditure, Burden of Disease and Management in 5 EU Countries 
NovoNordisk

Find out more here.

 


 

ms-mtrg-200-200

Improving Outcomes for People with Multiple Sclerosis (MS)
Roche

Find out more here.

 


 

ms-mtrg-200-200

Towards Better Outcomes in Multiple Sclerosis by Addressing Policy Change
Roche

Find out more here.

 


 

Europe-mtrg-200-200

The Use of Real World Evidence: Opportunities for Europe
Roche

Find out more here.

 


 

carcinoma-mtrg-200-200

Understanding the Hepatocellular Carcinoma (HCC) Patient Landscape: Results of the first global survey of people living with HCC
SIRTeX

Find out more here.

 

Grants

Impact HTA - Improved methods and actionable tools for enhancing HTA (2018-2021)

IMPACT HTA places strong emphasis on methodological improvements in the conduct of HTA and aims to produce tangible deliverables and toolkits that are immediately actionable by health care decision-makers and HTA agencies. Specifically, the overall objectives of IMPACT HTA are to:

  • contribute to the understanding of variations in costs and health outcomes within and across countries, the rationale and criteria for decision-making across different settings as well as the factors and preferences that shape HTA recommendations;
  • develop and disseminate innovative methodologies, toolkits and processes aiming to aid decision-making and improve efficiency in resource allocation in a number of areas including: extrapolation from RCT data; the development of a common and comparable dataset on health and social care costs across EU countries; quality of life measurement with emphasis on patient preference elicitation; methods of value assessment of medical technologies, including multi-criteria decision analysis; and how non-randomised studies can inform health economic evaluations; and
  • develop and disseminate tools facilitating EU-wide collaboration across Member State governments, HTA agencies, health care professionals, patients and the broader stakeholder community.

The thematic areas of focus of IMPACT HTA include:

  • The use of randomized controlled trial (RCT) and observational/registry data in economic evaluation;
  • The development of a costing methodology and a creation of a core dataset of (health and social care) costs for facilitating cross border comparisons in economic evaluation;
  • Capturing health preferences across different patient diagnoses using the EQ-5D-5L;
  • The analysis and interpretation of non-randomised studies to inform health economic evaluation;
  • The use of multi-criteria value methods and their relevance for HTA decision-making;
  • A model to analyse the determinants of HTA decision-making across countries and therapeutic areas ;
  • Economic evaluation methods for hospital-based assessments;
  • Measuring the fiscal impact of new healthcare interventions and incorporating this into HTA processes; and
  • HTA appraisal for orphan medicinal products.

Funder: European Commission – Horizon 2020

Partners:

  • The London School of Economics and Political Science – LSE Health (LSE), UK (coordinator)
  • The Andalusian School of Public Health (EASP), Spain
  • University of Castilla-La Mancha (UCLM), Spain
  • Universitaet Bielefeld (UNIBI), Germany
  • National Institute for Health and Care Excellence (NICE), UK
  • Instituto Superior Técnico (IST), Portugal
  • Paris School of Economics (PSE), France
  • Università Cattolica del Sacro Cuore (UCSC), Italy
  • Assistance Publique-Hôpitaux de Paris (AP-HP), France
  • Istituto Superiore di Sanità (ISS), Italy
  • Università Commerciale Luigi Bocconi (UB), Italy
  • University of Edinburgh (UEDIN), UK
  • Inštitut za Ekonomska Raziskovanja (IER), Slovenia
  • Agencja Oceny Technologii Medycznych i Taryfikacji (AOTMiT), Poland
  • Tandvårds- och läkemedelsförmånsverket (TLV), Sweden

MTRG team members: Panos Kanavos, Aris Angelis, Erica Visintin, Hala Hourani, Anna-Maria Fontrier, Mackenzie Mills and Olina Efthymiadou

Outputs: 

Summary of results
Final Workshop (agenda, presentations & recording) 

Visit the Impact HTA website

Mapping NCD - Mapping Chronic Non-Communicable Diseases (NCD) Research Activities and their Impact (2014-15)

Accurate mapping of NCD research can assist governments in understanding the most fruitful approaches to investing in an area which has direct economic consequences as well as social benefits. In addition, collaboration between public and private entities may further spread benefits and ensure greater likelihood of success. A broader perspective on currently existing national and European approaches to NCD funding might also be of great benefit to European countries in fine tuning their national strategies towards the development of more innovative solutions to the growing problem of NCDs. At EU level, NCD funding strategies are characterized by strong visions and policies. But there is also a need for new incentives in NCD R&D funding for the purpose of encouraging innovation and research that leads to better understandings of disease areas and also to new prevention strategies and improved treatments.

MAPPING NCD  maps European countries’ NCD research activities, investment and initiatives, and also quantifies their impact in five key disease areas: cardiovascular disease, chronic respiratory diseases, diabetes, cancer and mental health.  As a package, MAPPING NCD comprises a detailed qualitative survey of each of the five identified disease areas, a bibliometric analysis and an impact assessment.

Funder: European Union – 7th Framework Programme (FP7)

Partners:

  • London School of Economics (Coordinator - UK)
  • Technische Universitaet Berlin (Germany)
  • Escuela Andaluza de Salud Publica Granada (Spain)
  • Université Paris Est-Créteil (France)
  • King’s College London (UK)
  • Università Commerciale Luigi Bocconi (Italy)
  • Estonian Research Council (Estonia)

MTRG team members: Panos Kanavos, John Wright, Erica Visintin and Hala Hourani.

Outputs:

Final Deliverable
Brochure
Critical Appraisal: Cancer
Critical Appraisal: Cardiovascular Diseases
Critical Appraisal: Chronic Respiratory Diseases
Critical Appraisal: Diabetes
Critical Appraisal: Mental Health Disorders

Advance HTA – Rethinking the future of Health Technology Assessment (2013-15)

Advance-HTA aims to broaden the spectrum, complement and address areas of intense methodological debate in the application, use and implementation of HTA. It also aims to improve HTA methods, which can be taken further by competent authorities nationally whilst supplementing the work of supra-national bodies (e.g. EUnetHTA) towards a common understanding of choices in health care decision-making. For this purpose, ADVANCE-HTA focused on six distinct areas:

  • Value for money and the different approaches surrounding current thresholds for resource allocation. Advance-HTA systematically explored alternative means of assessing value for money and trace the implications for the conduct of HTA and the use of cost-effectiveness data to inform decision-making.
  • Value assessment and the factors that need to be considered and incorporated beyond cost effectiveness, such as burden of disease, disease severity, quality of the data and evidence produced, and the implications these are having on the continuous assessment of new health technologies and relative effectiveness. Advance-HTA aimed to explore new tools and methodologies in this domain, for example Multi-Criteria Decision Analysis, and investigate their adoption and implementation.
  • Assessment of rare diseases and the quality of the evidence required for and the methods associated with these assessments,relying on new data providing a more realistic understanding of the socio-economic benefits of orphan drugs. Advance-HTA developed and validated a framework to support decision-making relating to orphan drugs for rare diseases, by means of a Discrete Choice Experiment.
  • Elicitation of preferences and the robustness of the evidence derived from more realistic settings, by drawing on the wider EU citizenship and from within the patient community. Advance-HTA created new data that will incorporate patient-relevant values into widely used tools of quality-of-life measurement, such as the EQ-5D.
  • Medical devices and the suitability of current HTA tools across different categories, including diagnostics. Advance-HTA consolidated the current methods for assessing HTA in medical devices in different settings, address their suitability and propose how current tools can be modified or adapted in order to arrive at more robust methods of assessment.
  • HTA implementation and capacity building in settings outside Europe (Latin America and Eastern Europe), where HTA is beginning to be considered explicitly in decision-making. Advance-HTA created a framework for HTAs at different levels by benchmarking with evidence from countries that have developed such frameworks.

Funder: European Union – 7th Framework Programme (FP7)

Partners:

  • The London School of Economics and Political Science – LSE Health (LSE), UK
  • The London School of Hygiene and Tropical Medicine (LSHTM), UK
  • Istituto Superiore di Sanità (ISS), Italy
  • University of Castilla-La Mancha (UCLM), Spain
  • The Institute for Economic Research (IER), Slovenia
  • Technische Universität Berlin (TU Berlin), Germany
  • The Andalusian School of Public Health (EASP), Spain
  • Pan American Health Organisation (PAHO), USA
  • The European Brain Council (EBC), Belgium
  • University Paris-Est Créteil (UPEC), France
  • National Institute for Health and Clinical Excellence (NICE) - International, UK
  • Agency for Health Technology Assessment (AOTM), Poland
  • The Dental and Pharmaceutical Benefits Agency (TLV), Sweden

MTRG team members: Panos Kanavos, Elena Nicod, Aris Angelis and Hala Hourani.

Output: 

Final Deliverable

RARE Best Practices - A platform for sharing best practices for the management of rare diseases (2013-16)

A major challenge in the care of patients with rare diseases of yesterday and today, is a full and continuous access to accurate and up to date information on the treatment options. The project RARE-Best-Practices responds to the information needs of health professionals, patients, policy makers in the field of rare diseases, by creating a system of easily accessible resources for the development, evaluation, dissemination and implementation of guidelines for clinical practice, with the ultimate goal of improving the clinical management of rare diseases.

The MTRG led the project’s work package 5 - “Rare diseases technologies and value assessment”- whereby the team focused on:

  • understanding the criteria used by competent authorities in selected Member States in assessing the value of orphan medicines relying on evidence-based medicine (EBM) and cost-effectiveness analysis (CEA) in each jurisdiction
  • drawing on a selection of orphan drug appraisals in a number of EU countries over the January 2006 to December 2012 period and across therapeutic classes, to determine the criteria used to evaluate these drugs and the way clinical practice guidelines are developed across the selected sample of drugs; and
  • exploring Best Practices based on the evidence collected and share these across EU Member States.

Funder: European Union – 7th Framework Programme

Partners:

  • Istituto Superiore di Sanità - National Centre for Rare Diseases (coordinator)
  • Jamarau
  • Karolinska Institutet
  • Healthcare Improvement Scotland
  • London School of Economics and Political Science
  • National Research Council
  • EURORDIS, European Organisation for Rare Diseases
  • Associazione per la Ricerca sull'Efficacia dell'Assistenza Sanitaria Centro Cochrane Italiano
  • Universitaetsklinikum Freiburg
  • Bulgarian Association for Promotion of Education and Science
  • Fundación Canaria de Investigación y Salud
  • Universiteit Maastricht - Institute for Public Health Genomics (IPHG)
  • Newcastle University Upon Tyne
  • The European Academy of Paediatrics
  • Instituto de Salud Carlos III

MTRG team members: Panos Kanavos, Victoria Tzouma and David Tordrup

Output:

Tordrup D, Tzouma V, Kanavos P. Orphan drug considerations in Health Technology Assessment in eight European countries. Rare Dis Orphan Drugs 2014; 1(3):83-97-

Visit the RARE Best Practices website

BURQOL-RD - Social economic burden and health-related quality of life in patients with rare diseases in Europe (2010-2013)

Despite the low prevalence of Rare Diseases (RD) (5/10,000 persons), more than 5000 RD are recognised and hence, over 30 million EU citizens suffer from these conditions. Most cases RD are life-threatening, chronic and debilitating, requiring long term specialist and costly formal and informal care. The lack of effective diagnoses and treatments often underlies the shortened life expectancy and quality of life of these patients. These characteristics mean that RD require the combined efforts of health and social care professionals, politicians, managers and researchers to increase the availability of effective disease management tools to improve care and to extend both life expectancy and Health Related Quality of Life (HRQOL).

The main aim of BURQOL-RD is to generate a model to quantify the socio-economic costs and HRQOL, of both patients and caregivers, for ten RD in eight different European countries. This model is adaptable and sufficiently sensitive to capture the differences in the distinct Health and Social Care Systems in the EU Member States. As such the BURQOL-RD model provides an integrated and harmonised means to assess the impact of new public health policies, interventions and treatments for RD “in” and “among” EU Member States.

Funder: European Union - 2nd Programme of Community Action in the Field of Public Health

Partners:

  • Canary Foundation of Investigation and Health (FUNCIS), Spain (Coordinator)
  • Instituto de Salud Carlos III (ISCIII) – Research Institute for Rare Diseases (IIER), Spain
  • Instituto Superiore di Sanita (ISS), Italy
  • London School of Economics and Political Science (LSE-Health), UK
  • Bulgarian Association for Promotion of Education and Science (BAPES), Bulgaria Federación Española de Enfermedades Raras (FEDER), Spain
  • Leibniz University Hannover (LUH). Germany
  • The Swedish Institute for Health Economics (IHE), Sweden
  • Universita Commerciale “Luigi Bocconi” (Bocconi), Italy
  • University Paris Val de Marne (UPVM), France
  • Centre for Public Affairs Studies Foundation (CPASF), Hungary
  • Mario Negri Institute for Pharmacological Research (IRFMN), Italy

MTRG team members: Panos Kanavos, Aris Angelis and David Tordrup

Outputs:  

Angelis A, Kanavos P, López-Bastida J, Linertová R, Nicod E, Serrano-Aguilar P; BURQOL-RD Research Network. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Serv Res. 2015 Sep 28;15(1):428.

Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy. 2015 Jul;119(7):964-79.

 

Social/Economic Costs and Health-Related Quality of Life in Patients with Rare Diseases in Europe ​-​ ​Supplement in European Journal of Health Economics, Volume 17, Issue 1 Supplement, April 2016

 Aris Angelis, Panos Kanavos, Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Domenica Taruscio, Arrigo Schieppati, Georgi Iskrov, Valentin Brodszky, Johann Matthias Graf von der Schulenburg, Karine Chevreul, Ulf Persson, Giovanni Fattore and BURQOL-RD Research Network.

Visit the BURQOL-RD website

Twitter

LSE Health Policy LSEHealthPolicy

📣Job opportunity – Research officer The Department is looking for a research officer to join #LSEHealth to assess… twitter.com/i/web/status/1…

6 hours ago

Reply Retweet Favorite

LSE Health Policy LSEHealthPolicy

Study around full-time work with LSE’s Exec MSc in Health Economics and Management in Cardiovascular Sciences, in c… twitter.com/i/web/status/1…

7 hours ago

Reply Retweet Favorite

Contact us

Address

LSE Health, Cowdray House, London School of Economics and Political Science, Houghton Street, London WC2A 2AE

Follow us

Twiiter